Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation

Leukemia. 2004 Aug;18(8):1430-3. doi: 10.1038/sj.leu.2403412.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Cytarabine / administration & dosage*
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage*
  • Hematopoietic Stem Cell Transplantation / methods*
  • Hematopoietic Stem Cell Transplantation / mortality
  • Humans
  • Leukemia, Myeloid / mortality
  • Leukemia, Myeloid / therapy*
  • Lymphocyte Transfusion
  • Male
  • Middle Aged
  • Recurrence
  • Survival Analysis
  • Transplantation, Homologous

Substances

  • Cytarabine
  • Granulocyte-Macrophage Colony-Stimulating Factor